

Summit Adult Vaccination Recommendations Review (SAVRR) Council
Meeting Summary
September 8, 2026

Opening announcements

- Bob Hopkins (Co-chair) welcomed SAVRR Council members and reviewed the Council's scope and objectives.

Summary of Vaccine Integrity Project (VIP) evidence reviews and American Medical Association (AMA) tools and resources – AMA: Andrea Garcia; VIP: Sherri Berger and Clare Stoddart

VIP Evidence Review

- Methods for the VIP evidence reviews and a description of the study populations were reviewed.
- *Influenza conclusions*: Newly published evidence continues to demonstrate that influenza vaccines reduce the risk of severe disease, and no new safety concerns were identified, including among nearly 10 million people evaluated through post-marketing safety surveillance. High-level highlights were shared.
- *COVID-19 conclusions*: Evidence supports the effectiveness of COVID-19 vaccines at reducing the risk of hospitalization and mortality for those at high risk of severe disease, including older adults, infants, and during pregnancy. No new safety concerns were identified. High-level highlights were shared.
- *RSV conclusions*: RSV vaccination of older adults and pregnant women, along with infant immunization with monoclonal antibodies, substantially reduced severe illness and hospitalization. No new safety concerns were identified; full details of safety data are included in the review. High-level highlights were shared.
- Evidence Base for 2026-27 Respiratory Season Immunizations can be found [here](#).

AMA tools and resources

- AMA's new vaccine recommendations website, www.Spread the Facts.org, consolidates recommendations and resources for healthcare professionals and patients, sorted by pathogen and population. There are opportunities to include resources from other organizations.
- Resources for physicians and patients will continue to be added to the site, including an overarching recommendation infographic, FAQs, myths and facts, patient handouts, and implementation resources.
- Clinician webinar will be held on September 23 at 12:00 pm ET, including an overview from VIP on the structured, evidence-based review process, and representatives from the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians & Gynecologists (ACOG), and the Infectious Diseases Society of America (IDSA) will share their latest respiratory virus immunization recommendations and answer questions. Register [here](#).

- Dissemination toolkit is being developed and will include resources, messaging, and social assets focused on spreading the facts.
- A joint sign-on letter for support of the evidence review process and recommendations is planned.
- AMA will communicate with the public via a media tour in mid-to-late September.

Discussion

- The evidence review does not yet have sufficient data on revaccination with RSV vaccines.
- The new mRNA flu vaccine was included in the evidence review and is addressed in the AAFP recommendations.

Presentation of vaccination recommendations by medical societies

American Academy of Pediatrics (AAP)- Gillian Gibbs

- AAP's recommendation process was reviewed.
- AAP's 2026-27 respiratory virus season recommendations can be found [here](#).
 - Influenza vaccine had no changes.
 - COVID-19 vaccine had no changes.
 - Changes to RSV immunization second-season guidance:
 - Criteria for administration of RSV immunization in infants and children 8-19 months of age entering their second RSV season have been expanded to include the following conditions conferring higher risk of significant illness: children born preterm, and <32 weeks' gestation, regardless of the need for medication or other support; children with hemodynamically significant congenital heart disease; children with anatomic pulmonary abnormalities or neuromuscular disorders that put them at risk for severe disease; children with Down syndrome or other chromosomal differences placing them at higher risk of severe RSV disease.
 - Scope of AAP's evidence review was primarily on the safety and efficacy of the monoclonal antibody. Because of FDA indications and limited data in children <18 years of age, AAP did not make specific recommendations for RSV vaccine for immunocompromised adolescents who are 18 years of age and under for the 2026-2027 season. This may be in the scope of future AAP evidence reviews and recommendations as more research/data becomes available. For this respiratory season, IDSA focused on vaccine recommendations for immunocompromised populations.
- AAP's 2026 [child and adolescent immunization schedule](#) was published with updated notes for RSV, influenza, and COVID-19 to align with AAP policies. MenQuadfi (MenACWY-TT) minimum age changed to 6 weeks (from 2 years) for infants at high risk. See Addendum on page 18 for a detailed list of changes.

- AAP implementation resources are available, including [immunization fact sheets](#), [COVID vaccine dosing guide](#), and [RSV immunization visual guide](#).
- Webinar “Preparing for 2026-27 Respiratory Virus Season” will be held September 15 at 6:00 p.m. CT. Register [here](#).

American Academy of Family Physicians- Laura Morris

- AAFP develops immunization recommendations for nonpregnant, immunocompetent adults (age 19+ years) and health care personnel.
- AAFP’s recommendation process was reviewed.
- Influenza, COVID-19, and RSV vaccination recommendations can be found [here](#).
- AAFP recommends updated COVID-19 vaccination for all adults ages 19 years and older, which differs from the FDA indication that is limited to adults aged 65 and older or people under 65 years with at least one underlying condition that increases risk. However, qualifying risk factors are broad, and patients may self-attest to a risk factor.
- Actions to turn recommendations into routine practice were shared.

American College of Obstetrics & Gynecologists- L.J Tan on behalf of ACOG

- ACOG’s 2026-27 maternal immunization recommendations can be found [here](#).
- Practice advisories are available on [COVID-19 vaccination](#), [influenza vaccination](#), and [maternal RSV vaccination](#).
 - Updated RSV vaccination recommendation from ACOG states that pregnant women should be vaccinated through March 1 of the respiratory season and that administration of the vaccine can vary in jurisdictions within and outside the United States. The current Advisory Committee on Immunization Practices (ACIP) recommendation (2025) is to vaccinate through January 31, with jurisdictional guidance to determine if the deadline should be extended.
- ACOG’s [2026 maternal immunization schedule](#) has been endorsed by 15 medical associations.
- Patient resources are available [here](#).
- Webinar “Preparing for Respiratory Virus Season: Updated Maternal Immunization Guidance and Strategies” was held September 9 at 6:00 p.m. ET.

Infectious Diseases Society of America- Jon Heald

- IDSA’s guideline development policies, principles, and processes were reviewed.
- IDSA 2026 guidelines on the use of vaccines for the prevention of seasonal COVID-19, influenza, and RSV infections in immunocompromised patients can be found [here](#).
- The recommendations are unchanged from last season, but some remarks have been updated.

Discussion of potential implementation challenges

- IDSA was asked what evidence was available for the suggestion made about revaccination of immunocompromised persons with RSV vaccine (and at what interval), what age range should be used for its RSV vaccination recommendation for adolescents,

and also if they could define the term “second booster dose of COVID-19 vaccine”. Jon Heald will take these questions back to the IDSA panel to consider updating its guidance.

- AAFP and IDSA were asked about 6-month spacing recommendations between COVID-19 vaccinations, with no minimum intervals being specified. The established Centers for Disease Control and Prevention (CDC) minimum acceptable intervals between COVID-19 doses could be used for developing tools like standing orders.
- AAFP was asked if they could include clinical microbiologists as a recommended group for meningococcal vaccination, as they are a long-standing occupational high-risk group recommended for vaccination by CDC/ACIP.

American Pharmacists Association (APhA) perspectives on implementation challenges- Brigid Groves

- Pharmacy practice is governed in each state through administrative and legislative actions; therefore, pharmacists’ and pharmacy technicians’ authority to order and administer vaccines varies from state to state.
- Until recently, many states referred to the CDC and ACIP for which vaccines pharmacists had the authority to order and administer; however, many states have taken action to decouple from CDC/ACIP recommendations and now follow medical societies’ guidance.
- Patients should be able to access the flu vaccine from a pharmacist for the current respiratory season.
- Some states will have a prescription requirement for patients to receive COVID-19 vaccination through pharmacies. In these states, many large pharmacies have developed processes to easily allow a prescription to be requested from an individual’s provider electronically; smaller pharmacies may have more manual processes.
- The two states with the most challenges are Wisconsin (which is in the process of developing a standing order) and Louisiana.
- The Association of State and Territorial Health Officials (ASTHO) noted that CDC may release language on COVID-19 similar to what was recently released on influenza vaccination, which says that last year’s recommendations should continue into this year. Standing orders can also be developed at city, county, or hospital levels to address these issues.

Vaccinate Your Family’s (VYF) fall respiratory campaign- Diana Yassanye

- Theme is “Protect. Prepare. Prevent.”
- Campaign will run September through March and include influenza, COVID-19, RSV, and pneumococcal disease to align with messaging highlighted through the [National Respiratory Communications Initiative](#), which includes VYF, National Foundation for Infectious Diseases (NIFD), the National Adult and Influenza Immunization Summit, Immunize.org, and Association of Immunization Managers (AIM).
- Shareable social media graphics on lifespan vaccination in English and Spanish will be available on September 21 [here](#).
- They will launch a travel-centered paid campaign in November and December at all major airline hubs, giving people time to be vaccinated before they travel for the holidays.

America's Health Insurance Plans (AHIP) perspectives on insurance coverage- Kate Berry

- AHIP's membership covers a wide variety of insurance plans, including employee-sponsored insurance, Affordable Care Act plans, Medicaid, managed care, Medicare Advantage, etc.
- AHIP member plans intend to continue covering ACIP-recommended immunizations without cost-sharing through 2027, subject to applicable laws and plan requirements.
- AHIP [Statement on Vaccine Coverage](#) was updated in May 2026.
- AHIP doesn't anticipate any problems with insurance coverage for the new mRNA flu vaccine.
- Common Health Coalition shared its [Respiratory Season 2026-27 Explainer](#) and [State Vaccine Access Policy Tracker](#).

Immunize.org standing orders

- Standing order templates for the fall season are being updated now and are primarily focused on recommendations from AAP, AAFP, and ACOG.

Next meeting

- October 13
 - Closed session: 1:00 – 2:00 pm ET
 - Public meeting: 2:00 – 3:00 pm ET
- An additional meeting may be called before October to discuss outstanding implementation issues, such as the mRNA flu vaccine.